Anti-PD1 antibody toripalimab combined with lenvatinib, or GEMOX chemotherapy combined with lenvatinib as first-line therapy in patients with advanced intrahepatic cholangiocarcinoma: a randomized, open, two-cohort Phase 2 Study
Authors:
Open Access
- 21 October 2025
- journal article
- research article
- Published by Springer Nature in BMC Medicine
- Vol. 23 (1) , 1-14
Abstract
This research aimed to assess the efficacy and safety of a regimen combining lenvatinib with an anti-PD-1 antibody or chemotherapy in patients with advanced intrahepatic cholangiocarcinoma (ICC). A two-arm, open-label, phase II trial was carried out. Participants in Arm A received 240 mg of toripalimab intravenously on day 1 of each 3-week cycle, plus daily oral lenvatinib at 8 mg (< 60 kg) or 12 mg (≥60 kg). Participants in Arm B were administered the same daily lenvatinib in combination with GEMOX chemotherapy: 85 mg/m2 oxaliplatin on day 1, and 1 g/m2 gemcitabine on days 1 and 8 every 3 weeks for 6-8 cycles. The primary endpoint was the objective response rate (ORR) per RECIST 1.1, with secondary endpoints included treatment-related adverse events (AEs), overall survival (OS), and progression-free survival (PFS). Sixty one patients were recruited, with 31 in Arm A and 30 in Arm B. The ORR of Arm A was 32.3% (10/31; 95% CI: 16.7%–51.4%), and three patients underwent surgery after tumor downstaging. The median OS was 20.3 months (95% CI: 9.3–27.1), and median PFS was 8.9 months (95% CI: 4.2–13.9). Arm B showed an ORR of 40.0% (12/30; 95% CI: 22.7%–59.4%), and one patient proceeded to surgery after downstaging. Median OS was 15.5 months (95% CI: 9.6–23.8), and median PFS was 8.0 months (95% CI: 5.0–11.4). Adverse events (AEs) related to treatment were observed in most patients, with grade 3–4 AEs in 35.5% of Arm A and 40.0% of Arm B. The most frequent AEs were fatigue (71% vs. 63%), paresthesia (45% vs. 40%), and gingivitis (45% vs. 20%). Grade 4 thrombocytopenia occurred in 6.7% of Arm B. No grade 5 AEs were observed. Peripheral blood analysis showed monocyte levels decreased in PR(partial response) patients in Arm A but increased in PR patients in Arm B. The Combination of lenvatinib with either anti-PD-1 antibody or GEMOX chemotherapy is a well-tolerated and effective treatment for advanced ICC. ClinicalTrials.gov, NCT04361331Keywords
Funding Information
- National Natural Science Foundation of China (82273234, 81972232, 81830102)
- Shanghai Municipal Natural Science Foundation (21ZR1412200)
- Shanghai Municipal Key Clinical Specialty Construction Project (shslczdzk02401)
This publication has 25 references indexed in Scilit:
- Phase I/II study of nivolumab plus lenvatinib for advanced biliary tract cancer (JCOG1808/NCCH1817, SNIPE)ESMO Open, 2024
- Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet, 2023
- Interleukin-8: A chemokine at the intersection of cancer plasticity, angiogenesis, and immune suppressionPharmacology & Therapeutics, 2020
- A Phase 2 Multi-institutional Study of Nivolumab for Patients With Advanced Refractory Biliary Tract CancerJAMA Oncology, 2020
- Systemic therapies for intrahepatic cholangiocarcinomaJournal of Hepatology, 2020
- Lenvatinib: A Review in Hepatocellular CarcinomaDrugs, 2019
- Intrahepatic cholangiocarcinoma: Epidemiology, risk factors, diagnosis and surgical managementCancer Letters, 2016
- Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trialThe Lancet Oncology, 2014
- Transarterial chemoembolization versus supportive therapy in the palliative treatment of unresectable intrahepatic cholangiocarcinomaClinical Radiology, 2011
- Gemcitabine and oxaliplatin in patients with unresectable biliary cancer including gall bladder cancer: a Korean Cancer Study Group phase II trialCancer Chemotherapy and Pharmacology, 2009